Neisseria meningitidis showing decreased susceptibility to ciprofloxacin: first report in Spain

Alcalá, Belén; Salcedo, Celia; Fuente, Laura de la; Arreaza, L.; Uría, María José; Abad, Raquel; Enriquez, Rocío; Vázquez, Julio A.; Motgé, M.; Batlle, Jordi de

doi:10.1093/jac/dkh075

Cited by 27 publications

(18 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, ciprofl oxacin-resistant serogroup A N. meningitidis has not been reported anywhere in the world. Four reports of sporadic instances of decreased susceptibility to ciprofl oxacin: serogroup B from France in 1999 and Spain in 2002, serogroup C from Australia in 1998, and serogroup Y from Argentina in 2002 (4)(5)(6). For the fi rst time, to our knowledge, we report the emergence of decreased susceptibility of serogroup A N. meningitidis to ciprofl oxacin from the 2005 outbreak in Delhi.…”

mentioning

confidence: 75%

Ciprofloxacin-ResistantNeisseria meningitidis, Delhi, India

Singhal¹,

Purnapatre²,

Kalia³

et al. 2007

Emerg. Infect. Dis.

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 75%

Ciprofloxacin-ResistantNeisseria meningitidis, Delhi, India

Singhal¹,

Purnapatre²,

Kalia³

et al. 2007

Emerg. Infect. Dis.

View full text Add to dashboard Cite

show abstract

“…The majority of the NM with no susceptibility to ciprofloxacin reported to date present gyr A mutations, and the alteration at Thr91-Ile seems to be the most common [40], [42]. This mutation was originally described in Spain 2003 [43] and subsequently found in 11 serogroup A strains from New Delhi, India [44], [45], as well as in three serogroup B strains from the USA [42], [46], [47]. The non-susceptibility to ciprofloxacin was detected for first time in serogroup W135 during 2008 in two NM strains from Spain (Thr91-Ile) and in one from France (Thr91-Ile) [40], [48].…”

Section: Discussionmentioning

confidence: 99%

Phenotypic and Genotypic Characteristics of Neisseria meningitidis Disease-Causing Strains in Argentina, 2010

et al. 2013

View full text Add to dashboard Cite

Phenotypic and genotypic characterization of 133 isolates of Neisseria meningitidis obtained from meningococcal disease cases in Argentina during 2010 were performed by the National Reference Laboratory as part of a project coordinated by the PAHO within the SIREVA II network. Serogroup, serotype, serosubtype and MLST characterization were performed. Minimum Inhibitory Concentration to penicillin, ampicillin, ceftriaxone, rifampin, chloramphenicol, tetracycline and ciprofloxacin were determined and interpreted according to CLSI guidelines. Almost 49% of isolates were W135, and two serotype:serosubtype combinations, W135∶2a:P1.5,2:ST-11 and W135∶2a:P1.2:ST-11 accounted for 78% of all W135 isolates. Serogroup B accounted for 42.1% of isolates, and was both phenotypically and genotypically diverse. Serogroup C isolates represented 5.3% of the dataset, and one isolate belonging to the ST-198 complex was non-groupable. Isolates belonged mainly to the ST-11 complex (48%) and to a lesser extent to the ST-865 (18%), ST-32 (9,8%) and the ST-35 complexes (9%). Intermediate resistance to penicillin and ampicillin was detected in 35.4% and 33.1% of isolates respectively. Two W135∶2a:P1.5,2:ST-11:ST-11 isolates presented resistance to ciprofloxacin associated with a mutation in the QRDR of gyrA gene Thr91-Ile. These data show serogroup W135 was the first cause of disease in Argentina in 2010, and was strongly associated with the W135∶2a:P1.5,2:ST-11 epidemic clone. Serogroup B was the second cause of disease and isolates belonging to this serogroup were phenotypically and genotypically diverse. The presence of isolates with intermediate resistance to penicillin and the presence of fluorquinolone-resistant isolates highlight the necessity and importance of maintaining and strengthening National Surveillance Programs.

show abstract

“…Meningococcal resistance to fluoroquinolones has been rarely reported and only at a low level (MIC 0.12-0.25 mg/L): one strain in Greece [40], a few strains in England and Wales [41]; France [42]; Spain [43]. The potential for the development of this resistance is similar, according to in vitro studies, to those seen in quinolone-resistant N. gonorrhoeae strains with alterations in gyrA and parC genes [44].…”

Section: Antibiotic Susceptibilitymentioning

confidence: 99%